AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03133533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robot-assisted repair
Description: Surgical inguinal hernia repair using robot-assisted approach.
Study NCT02075463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
Study NCT02075463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet for GSK1278863
Study NCT02700776 — intervention group
Intervention type: OTHER
Intervention: Phlebotomy - Blood sampling for GP88 at MM
Description: Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.
Study NCT02700776 — intervention group
Intervention type: PROCEDURE
Intervention: SOC Tissue biopsy
Description: standard of care tissue biopsy if clinically indicated.
Study NCT03174847 — intervention group
Intervention type: PROCEDURE
Intervention: Adrenalectomy
Description: Adrenalectomy for unilateral adrenal hyperplasia / adenoma
Study NCT03174847 — intervention group
Intervention type: DRUG
Intervention: Mineralocorticoid Receptor Antagonists
Description: Medical treatment with MRA / amiloride
Study NCT00239577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated tetravalent dengue vaccine
Description: Live attenuated tetravalent dengue vaccine
Study NCT00239577 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02704585 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nellcor
Description: Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
Study NCT02704585 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Masimo
Description: Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
Study NCT03394235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-pulsed, 1064nm Nd-YAG laser
Description: This long-pulsed Nd-YAG laser is commonly used for laser hair removal and vascular lesions, but in this study it is used to reduce the size of the hair shaft at the occipital area.
Study NCT01300676 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tualang honey
Description: This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
Study NCT01300676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tualang honey
Description: This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
Study NCT04270721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EAGLE Safe Anastomosis Quality Improvement Intervention
Description: The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts:~1. Introduction of a routine patient risk stratification for anastomotic leak~2. Implementation of the ESCP Safe Anastomosis Checklist~3. Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence.
Study NCT03597243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash Transfer
Description: Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
Study NCT00546988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplant
Study NCT03538327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silybin
Description: After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
Study NCT00906477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified CI therapy
Description: 10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
Study NCT00906477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified CI therapy
Description: 10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
Study NCT05244863 — intervention group
Intervention type: OTHER
Intervention: Test
Description: Measurements
Study NCT01975948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Practice Support Program
Description: 1. training and (2) practice support.~   * Three half day workshop sessions over a 24 week period.~  * Practice support:~     3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes
Study NCT01975948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Physicians manage patients with depression as usual
Study NCT00931697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD 452 (+) mefloquine
Description: Single dose delivered as over-encapsulated tablet at ascending doses
Study NCT00931697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Mefloquine
Description: Single dose delivered as over-encapsulated tablet at ascending dose
Study NCT00931697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over-encapsulated placebo to maintain blinding
Study NCT01299454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712
Description: All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
Study NCT03502148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRV111 (Cisplatin Transmucosal System)
Description: Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
Study NCT02124135 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet/Nutrition Education
Description: As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant.
Study NCT02124135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet/Nutrition Education
Description: As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant.
Study NCT02232776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Dose of Losartan : 0.7mg/kg once daily.
Study NCT01212848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.
Study NCT01212848 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation - Sham Comparator
Description: The control group will receive an identical dosing schedule of sham repetitive TMS over three days.
Study NCT01621893 — intervention group
Intervention type: PROCEDURE
Intervention: Subchondroplasty
Study NCT04330534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: BCX9930 capsules for oral administration
Study NCT04330534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match BCX9930 capsules for oral administration
Study NCT00982397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protecta VR-ICD
Description: Protecta single-chamber implantable cardioverter defibrillators.
Study NCT00982397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protecta DR-ICD or CRT-D
Description: Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
Study NCT02885285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinning Class
Description: Spinning Class twice a week for six weeks.
Study NCT02885285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Class
Description: Yoga Class twice a week for six weeks.
Study NCT02885285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Class
Description: Dance Class twice a week for six weeks.
Study NCT02885285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Exercise Class
Description: No exercise class. Subject will continue regular activities for six weeks.
Study NCT02326935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose derived mesenchymal cells
Description: Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.
Study NCT00600561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSR
Description: Mindfulness-Based Stress Reduction Intervention
Study NCT00600561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness-Based Stress Reduction Intervention
Study NCT00434616 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone marrow cell concentrate transplantation
Description: bone marrow aspiration (240 ml), processing and reinjection
Study NCT00434616 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: saline injections
Study NCT03834636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorations with nanoparticulated composites and self etch adhesives
Description: The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanoparticulated composite (Z350, 3M ESPE)
Study NCT03834636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorations with nanoparticulated composites and total-etch adhesives
Description: The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanoparticulated composite (Z350, 3M ESPE)
Study NCT03834636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorations with nanohybrid composites and self etch adhesives
Description: The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
Study NCT03834636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorations with nanohybrid composites and total-etch adhesives
Description: The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
Study NCT00417456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evisit
Description: Asynchronous,remote care delivery via a secure web platform
Study NCT00417456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office visit
Description: Conventional office-based care
Study NCT03538964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: toric intraocular lens
Description: cataract surgery with implantation of an toric intraocular lens
Study NCT00433537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00433537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT04534790 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiotherapy
Description: anti-inflammatory effect with low-dose radiation to the lungs
Study NCT03606408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: osilodrostat
Description: osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
Study NCT04358874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation
Description: Medicines currently being taken will be reviewed and compared to the medicines that were prescribed at discharge.
Study NCT04358874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication reconciliation
Description: Medicines currently being taken will be reviewed and compared to the medicines that were prescribed at discharge.
Study NCT04358874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Pressure Management
Description: Blood pressure will be checked at follow-up visits and medicines will be adjusted if blood pressure is above target range (>160/100)
Study NCT04358874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Management
Description: Blood pressure will be checked at follow-up visits and medicines will be adjusted if blood pressure is above target range (>160/100)
Study NCT00433537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT01796730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bambuterol
Description: Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
Study NCT01796730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04108572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant feeding
Description: Verbally delivered pre-specified infant feeding message. The messages focus on appropriate milk feeding and establishing complementary feeding and solid food introduction in relation to timing and practical guidance around processes of feeding and provision of additional infant-feeding resources including information leaflet, a magnet, an infant bib and access to an informational website.
Study NCT03538964 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non toric intraocular lens
Description: cataract surgery with implantation of a non toric intraocular lens
Study NCT04028440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous γδT cells
Description: Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
Study NCT00433537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV
Study NCT00433537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study NCT00433537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00433537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC
Study NCT00433537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Study NCT00792389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm humidified C02
Description: Insufflation of warmed humidified gas during laparoscopic cholecystectomy
Study NCT00792389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cool dry C02
Description: Insufflation of cool dry gas during laparoscopic cholecystectomy
Study NCT01364493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Capecitabine+Oxaliplatin
Description: Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles
Study NCT02009774 — intervention group
Intervention type: PROCEDURE
Intervention: NBI Function
Study NCT00732082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT00732082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00732082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG-3
Study NCT03546283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
Study NCT03546283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cattle Encephalon Glycoside and Ignotin
Description: The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
Study NCT03387072 — intervention group
Intervention type: OTHER
Intervention: Non interventional study
Description: mental stress test and Blood (or salivary) sample
Study NCT00593463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
Study NCT00593463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Diltiazem: 30, 60, 120 mg oral capsule may possibly be
Study NCT00593463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
Study NCT00593463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine
Description: Isradipine: 5, 10 mg oral capsule may possibly be given
Study NCT00593463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
Study NCT00593463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
Study NCT00593463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
Study NCT00593463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline: I.M. injection may possibly be given
Study NCT00593463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil: 30, 60, 120 mg oral capsule may possibly be given